ALNYLAM PHARMACEUTICALS, INC. (ALNY) earnings date
Feb 11, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 30 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Oct 29, 2026 | before open | 29 | 8-K |
| Q2 FY2026 | Thu, Jul 30, 2026 | before open | 30 | 8-K |
| Q1 FY2026 | Thu, Apr 30, 2026 | before open | 30 | 8-K |
| Q4 FY2025 | Thu, Feb 12, 2026 | before open | 43 | 8-K |
| Q3 FY2025 | Thu, Oct 30, 2025 | before open | 30 | 8-K |
| Q2 FY2025 | Thu, Jul 31, 2025 | before open | 31 | 8-K |
| Q4 FY2024 | Mon, Jan 13, 2025 | before open | 13 | 8-K |
| Q4 FY2023 | Thu, Feb 15, 2024 | before open | 46 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Bo Piela (Media) 508-308-9783 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress − Generated Third Quarter 2026 Global Net Product Revenues of $1,292 Million (52% Growth Compared with Q3 2025), Driven Primarily by Total TTR Revenues of $1,150 Million (59% Growth Compared with Q3 2025) – − Expands Target Enrollment in TRITON-CM Phase 3 Study of Nucresiran to 2,250 Patients; Study Design Continues to Support Expected ATTR-CM Launch by 2030 – " exhibit |
| Q3 FY2026 | "Given the rapid pace of enrollment and the event-driven nature of the study’s primary endpoint, the Company still expects to launch nucresiran, assuming positive data and regulatory approval, in ATTR-CM by 2030." exhibit |
| Q3 FY2026 | "Presented preclinical data and Phase 1 design details at AAIC 2026 for ALN-5288 , an investigational RNAi therapeutic targeting microtubule-associated protein tau (MAPT) for Alzheimer's disease and tauopathies." exhibit |
| Q3 FY2026 | "The Company now expects to announce clinical data from the Phase 2 trial of ALN-6400 in patients with hereditary hemorrhagic telangiectasia (HHT), as well as from the Phase 1 trial of ALN-2232 in obesity and weight management, in conjunction with its fourth quarter and full year 2026 earnings call in February 2027." exhibit |
| Q3 FY2026 | "A reconciliation of our GAAP to non-GAAP financial results is included in the tables at the end of this press release. 2026 Financial Guidance Full-year 2026 financial guidance is reiterated and consists of the following: Item FY 2026 Guidance Total TTR net product revenues (AMVUTTRA, ONPATTRO) 1 $4,200 million - $4,500 million Total Rare net product revenues (GIVLAARI, OXLUMO) 1 $500 million - $600 million Total net product revenues 1 $4,700 million - $5,100 million Net product revenues growth vs. 2025 at currency exchange rates as of June 30, 2026 1 57% to 71% Net product revenues growth vs." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Bo Piela (Media) 508-308-9783 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress − Achieved Second Quarter 2026 Global Net Product Revenues of $1,172 Million (74% Growth Compared with Q2 2025), Driven Primarily by Total TTR Revenues of $1,030 Million (89% Growth Compared with Q2 2025) – − Revises Full-Year 2026 TTR Net Product Revenue Guidance from $4,400 to $4,700 Million to $4,200 to $4,500 Million (75% Growth Compared with 2025 at Revis" exhibit |
| Q2 FY2026 | "We have lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy." exhibit |
| Q2 FY2026 | "Presented preclinical data and Phase 1 design details at AAIC 2026 for ALN-5288 , an investigational RNAi therapeutic targeting microtubule-associated protein tau (MAPT) for Alzheimer's disease and tauopathies." exhibit |
| Q2 FY2026 | "Monday, October 26, 10:00 am ET In the second half of 2026, Alnylam expects to announce clinical data from additional pipeline programs, including:" exhibit |
| Q2 FY2026 | "Net revenues from collaborations decreased during the three months ended June 30, 2026, as compared to the same period in 2025, due to lower revenue recognized under our Regeneron collaboration, partially offset by increased revenue under our Roche collaboration driven by higher reimbursable development activities related to the ZENITH Phase 3 clinical trial of zilebesiran." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ALNY
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ALNY
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ALNY/"><img src="https://veritasdata.dev/embed/ALNY.svg" alt="ALNY earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ALNY/)
Script
<script async src="https://veritasdata.dev/embed/ALNY.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ALNY"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.